FDA Approves Lynparza as Adjuvant Treatment in Early-Stage, BRCA1/2-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
The British-Swedish pharma and biotechnology giant is “optimistic” about rapidly providing them
Seven medicines already approved as changes cut as much as a month off approval times
LONDON (dpa-AFX) - AstraZeneca (AZN.L, AZN) announced Thursday new data in liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza.The company noted that
AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022